With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

Represents the first PD-1 inhibitor plus ADC regimens for this patient population These approvals are based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

Shared decision-making in ALK-positive NSCLC is crucial, with patient-authored guides aiding in managing lorlatinib side effects and empowering patients. Newly diagnosed lung cancer patients benefit ...